| Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy (NCT04319198) | Gilead Sciences | 2020-08-04 |
| First in Human Study of M6223 (NCT04457778) | EMD Serono Research & Development Institute, Inc. | 2020-07-10 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations (NCT04094610) | Turning Point Therapeutics, Inc. | 2020-03-12 |
| Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (NCT03993873) | Turning Point Therapeutics, Inc. | 2019-09-05 |
| A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors (NCT03910530) | Incyte Biosciences Japan GK | 2019-07-22 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (NCT03893955) | AbbVie | 2019-05-21 |
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours (NCT03697304) | Boehringer Ingelheim | 2019-03-19 |
| A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (NCT03854227) | Pfizer | 2019-03-14 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors (NCT03802123) | ImaginAb, Inc. | 2018-12-18 |
| Imaging of Advanced Tumours Using [131]I-IAZA (NCT03427320) | University of Alberta | 2018-12-01 |
| A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03646071) | NeuPharma, Inc. | 2018-08-01 |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. (NCT03573544) | OBI Pharma, Inc | 2018-05-07 |
| Phase I/Ib Multiple Ascending Dose Study in China (NCT03523390) | Merck KGaA, Darmstadt, Germany | 2018-04-24 |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (NCT03388632) | National Cancer Institute (NCI) | 2018-02-05 |
| MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study (NCT03403725) | Menarini Group | 2017-08-28 |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (NCT03093116) | Turning Point Therapeutics, Inc. | 2017-03-07 |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors (NCT03059823) | Incyte Corporation | 2016-11-15 |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study (NCT04010240) | Institut Bergonié | 2015-12-23 |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors (NCT02281409) | Memorial Sloan Kettering Cancer Center | 2014-10-01 |
| Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors (NCT02235688) | ImmunityBio, Inc. | 2014-08-01 |
| A Study of DCC-2701 in Participants With Advanced Solid Tumors (NCT02228811) | Deciphera Pharmaceuticals, LLC | 2014-06-01 |
| A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety (NCT01976143) | Nektar Therapeutics | 2014-02-01 |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors (NCT02045602) | Theriva Biologics SL | 2014-01-01 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors (NCT01928459) | Novartis Pharmaceuticals | 2013-10-01 |
| A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors (NCT01847118) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2013-04-01 |
| Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors (NCT01543763) | Pamela Munster | 2012-06-25 |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer (NCT01449370) | Millennium Pharmaceuticals, Inc. | 2011-10-01 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors (NCT00793897) | Bristol-Myers Squibb | 2009-04-01 |
| A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors (NCT00827203) | Synta Pharmaceuticals Corp. | 2009-01-01 |
| Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors (NCT00878423) | Astex Pharmaceuticals, Inc. | 2008-05-01 |
| Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) (NCT00670488) | Merck Sharp & Dohme LLC | 2008-04-15 |
| Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study. (NCT00159016) | Hadassah Medical Organization | 2002-08-01 |
| Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. (NCT00149019) | Hadassah Medical Organization | 2002-05-01 |
| Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors (NCT00148993) | Hadassah Medical Organization | 1998-07-01 |